WO2005049040A1 - Combinations comprising ampa receptor antagonists for the treatment of schizophrenia - Google Patents
Combinations comprising ampa receptor antagonists for the treatment of schizophrenia Download PDFInfo
- Publication number
- WO2005049040A1 WO2005049040A1 PCT/EP2004/012150 EP2004012150W WO2005049040A1 WO 2005049040 A1 WO2005049040 A1 WO 2005049040A1 EP 2004012150 W EP2004012150 W EP 2004012150W WO 2005049040 A1 WO2005049040 A1 WO 2005049040A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- schizophrenia
- aliphatic
- administered
- combination according
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to combinations suitable for the treatment of psychiatric/neurological disorders, in particular schizophrenia.
- a combination which comprises at least one AMPA receptor antagonist and at least one compound selected from the group consisting of (a) anti-epileptic drugs selected from barbiturates and derivatives thereof, benzodiazepines, carboxamides, hydantoins, succinimides, valproic acid and other fatty acid derivates and other anti-epileptic drugs, (b) conventional antipsychotics and (c) atypical antipsychotics is greater than the additive effect of the combined drugs.
- the combinations disclosed herein can be used to treat schizophrenia which is refractory to monotherapy employing one of the combination partners alone.
- the invention relates to a combination, such as a combined preparation or pharmaceutical composition, which comprises at least one AMPA receptor antagonist and at least one compound selected from the group consisting of (a) anti-epileptic drugs selected from barbiturates and derivatives thereof, benzodiazepines, carboxamides, hydantoins, succinimides, valproic acid and other fatty acid derivates and other anti-epileptic drugs, (b) conventional antipsychotics and (c) atypical antipsychotics, in which the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt and optionally at least one pharmaceutically acceptable carrier; for simultaneous, separate or sequential use.
- a compound selected from the group consisting of (a) anti-epileptic drugs selected from barbiturates and derivatives thereof, benzodiazepines, carboxamides, hydantoins, succinimides, valproic acid and other fatty acid derivates and other anti-epileptic drugs, (
- AMPA receptor antagonists as used herein includes, but is not limited to the quinoxaline-dione aminoalkylphosphonat.es of formula I
- Ri represents hydroxy or an aliphatic, aryl aliphatic or aromatic group
- X represents an aliphatic, cycloaliphatic, cycloaliphatic aliphatic, aryl aliphatic, heteroaryl aliphatic or aromatic group
- R 2 represents hydrogen or an aliphatic or aryl aliphatic group, alk stands for C1-C7alkylene, and
- R 3 , R 4 and R 5 represent independently of each other hydrogen, C1-C7alkyl, halogen, trifluoromethyl, cyano or nitro, and wherein the radicals have the meanings as defined in WO 98/17672.
- AMPA receptor antagonists include also, EGIS 8332 (7-acetyl-5-(4-aminophenyl)-8,9- dihydro- ⁇ -methyl-ZH-I .S-dioxolo ⁇ . ⁇ -hJp.Slbenzodiazepine- ⁇ -carbonitrile), GYKI 47261 (4- (7-chloro-2-methyl-4H-3,10,10a-triaza-benzo[f]azulen-9-yl)-phenylamine), irampanel (BUR 561; N,N-dimethyl-2-[2-(3-phenyl-1 ,2,4-oxadiazol-5-yl)phenoxy]ethanamine), KRP 199 (7-[4- [[[[[(4-carboxyphenyl)-amino]carbonyl]oxy]methyl]-1H-imidazol-1-yl]-3,4-dihydro-3-oxo-6- (trifluoromethyl)-2-quinoxa
- YM90K (6-imidazol-1-yl-7-nitro-1 ,4- dihydro-quinoxaline-2,3-dione), S-34730 (7-chloro-6-sulfamoyl-2-(1 H)-quinolinone-3- phosphonic acid), Zonampanel (YM-872; (7-imidazol-1-yl-6-nitro-2,3-dioxo-3,4-dihydro-2H- quinoxalin-1-yl)-acetic acid), GYKI-52466 (4-(8-methyl-9H-1,3-dioxa-6,7-diaza- cyclohepta[f]inden-5-yl)-phenylamine), ZK-200775 (MPQX, (7-morpholin-4-yl-2,3-dioxo-6- trifluoromethyl-3,4-dihydro-2H-quinoxaIin-1-ylmethyl)-phosphonic acid), CP
- the term "barbiturates and derivatives thereof as used herein includes, but is not limited to phenobarbital, pentobarbital, mepobarbital and primidon.
- benzodiazepines as used herein includes, but is not limited to clonazepam, diazepam and lorazepam.
- carboxyamides as used herein includes, but is not limited to carbamazepine, oxcarbazepine, 10-hydroxy-10,11-dihydrocarbamazepine and the compounds of formula II
- R represents C-
- hydantoins as used herein includes, but is not limited to phenytoin.
- succinimides as used herein includes, but is not limited to ethosuximide, phensuximide and mesuximide.
- valproic acid and other fatty acid derivates as used herein includes, but is not limited to valproic acid sodium salt, tiagabine hydrochloride monohydrate and vigrabatrine.
- other anti-epileptic drugs includes, but is not limited to levetiracetam, lamotrigine, gabapentin, sultiam, felbamate, the 1 ,2,3-1 H-triazoles disclosed in EP 114 347 and the 2-aryl-8-oxodihydro- purines disclosed in WO99/28320.
- conventional antipsychotics includes, but is not limited to haloperidol, fluphenazine, thiotixene and flupentixol.
- atypical antipsychotics as used herein relates to clozaril, risperidone, olanzapine, quetiapine, ziprasidone and aripiprazol.
- the structure of the active ingredients identified by code nos., generic or trade names and their preparation may be taken from the actual edition of the standard compendium "The Merck Index” (e.g.M. J. O'Neil et al., ed., The Merck Index', 13 th ed., Merck Research Laboratories, 2001) or from databases, e.g. Patents International (e.g. IMS World Publications). The corresponding content thereof is hereby incorporated by reference. Any person skilled in the art is fully enabled to identify the active ingredients and, based on these references, likewise enabled to manufacture and test the pharmaceutical indications and properties in standard test models, both in vitro and in vivo.
- Phenobarbital can be administered, e.g., in the form as marketed, e.g. under the trademark LuminalTM.
- Primidon can be administered, e.g., in the form as marketed, e.g. under the trademark MylepsinumTM.
- Clonazepam can be administered, e.g., in the form as marketed, e.g. under the trademark AntelepsinTM.
- Diazepam can be administered, e.g., in the form as marketed, e.g. under the trademark Diazepam DesitinTM.
- Lorazepam can be administered, e.g., in the form as marketed, e.g. under the trademark TavorTM.
- Carbamazepine can be administered, e.g., in the form as marketed, e.g. under the trademark TegretalTM or TegretolTM.
- Oxcarbazepine can be administered, e.g., in the form as marketed, e.g. under the trademark TrileptalTM.
- Oxcarbazepine is well known from the literature [see for example Schuetz H. et al., Xenobiotica (GB), 16(8), 769-778 (1986)].
- the preparation of the compound of formula II wherein R ⁇ is CrC 3 alkyl carbonyl and its pharmaceutically acceptable salts is described, e.g., in US 5,753,646.
- 10-Hydroxy-10,11-dihydro- carbamazepine can be prepared as disclosed in US 3,637,661. 10-Hydroxy-10,11- dihydrocarbamazepine may be administered, e.g., in the form as described in US 6,316,417. Phenytoin can be administered, e.g., in the form as marketed, e.g. under the trademark EpanutinTM. Ethosuximide can be administered, e.g., in the form as marketed, e.g. under the trademark SuxinutinTM. Mesuximide can be administered, e.g., in the form as marketed, e.g. under the trademark PeeckinTM.
- Valproic acid sodium salt can be administered, e.g., in the form as marketed, e.g. under the trademark LeptilanTM.
- Tiagabine hydrochloride monohydrate can be administered, e.g., in the form as marketed, e.g. under the trademark GabitrilTM.
- Vigabatrine can be administered, e.g., in the form as marketed, e.g. under the trademark SabrilTM.
- Levetiracetam can be administered, e.g., in the form as marketed, e.g. under the trademark KeppraTM.
- Lamotrigine can be administered, e.g., in the form as marketed, e.g. under the trademark LamictalTM.
- Gabapentin can be administered, e.g., in the form as marketed, e.g. under the trademark NeurontinTM.
- Sultiam can be administered, e.g., in the form as marketed, e.g. under the trademark OspolotTM.
- Felbamate can be administered, e.g., in the form as marketed, e.g. under the trademark TaloxaTM.
- Topiramate can be administered, e.g., in the form as marketed, e.g. under the trademark TopamaxTM.
- the 1 ,2,3-1 H-triazoles disclosed in EP 114 347 may be administered, e.g., in the form as described in US 6,455,556.
- the 2-aryl-8-oxodihydropurines disclosed in WO99/28320 may be administered, e.g., in the form as described in WO99/28320.
- Haloperidol can be administered, e.g., in the form as marketed, e.g. under the trademark Haloperidol STADATM.
- Fluphenazine can be administered, e.g., in the form of its dihydrochloride as marketed, e.g. under the trademark ProlixinTM.
- Thiothixene can be administered, e.g., in the form as marketed, e.g. under the trademark NavaneTM. It can be prepared, e.g., as described in US 3,310,553.
- Flupentixol can be administered for instance in the form of its dihydrochloride, e.g., in the form as marketed, e.g. under the trademark EmergilTM or in the form of its decanoate, e.g., in the form as marketed, e.g. under the trademark DepixolTM. It can be prepared, e.g., as described in BP 925,538. Clozaril can be administered, e.g., in the form as marketed, e.g. under the trademark LeponexTM. It can be prepared, e.g., as described in US 3,539,573. Risperidone can be administered, e.g., in the form as marketed, e.g.
- Olanzapine can be administered, e.g., in the form as marketed, e.g. under the trademark ZyprexaTM.
- Quetiapine can be administered, e.g., in the form as marketed, e.g. under the trademark SeroquelTM.
- Ziprasidone can be administered, e.g., in the form as marketed, e.g. under the trademark GeodonTM. It can be prepared, e.g., as described in GB 281 ,309.
- Aripiprazole can be administered, e.g., in the form as marketed, e.g. under the trademark AbilityTM. It can be prepared, e.g., as described in US 5,006,528.
- Topiramate can be administered, e.g., in the form as marketed, e.g. under the trademark TopamaxTM.
- TopamaxTM e.g., the trademark of TopamaxTM.
- the compounds of formula I as well as their production process and pharmaceutical compositions thereof are known e.g. from WO 98/17672.
- a combined preparation defines especially a "kit of parts" in the sense that the first and second active ingredient as defined above can be dosed independently or by use of different fixed combinations with distinguished amounts of the ingredients, i.e., simultaneously or at different time points.
- the parts of the kit of parts can then, e.g., be administered simultaneously or chronologically staggered, that is at different time points and with equal or different time intervals for any part of the kit of parts.
- the time intervals are chosen such that the effect on the treated disease in the combined use of the parts is larger than the effect which would be obtained by use of only any one of the active ingredients.
- the ratio of the total amounts of the active ingredient 1 to the active ingredient 2 to be administered in the combined preparation can be varied, e.g., in order to cope with the needs of a patient sub-population to be treated or the needs of the single patient which different needs can be due to age, sex, body weight, etc. of the patients.
- there is at least one beneficial effect e.g., a mutual enhancing of the effect of the first and second active ingredient, in particular a synergism, e.g. a more than additive effect, additional advantageous effects, less side effects, a combined therapeutically effect in a non-effective dosage of one or both of the first and second active ingredient, and especially a strong synergism the first and second active ingredient.
- references to the active ingredients are meant to also include the pharmaceutically acceptable salts. If these active ingredients have, for example, at least one basic center, they can form acid addition salts. Corresponding acid addition salts can also be formed having, if desired, an additionally present basic center.
- the active ingredients having an acid group (for example COOH) can also form salts with bases.
- the active ingredient or a pharmaceutically acceptable salt thereof may also be used in form of a hydrate or include other solvents used for crystallization.
- a pharmaceutical combination which comprises at least one AMPA antagonist and at least one compound selected from the group consisting of (a) anti-epileptic drugs selected from barbiturates and derivatives thereof, benzodiazepines, carboxamides, hydantoins, succinimides, valproic acid and other fatty acid derivates and other anti-epileptic drugs, (b) conventional antipsychotics and (c) atypical antipsychotics, in which the active ingredients are present in each case in free form or in the form of a pharmaceutically acceptable salt, if at least one salt-forming group is present, will be referred to hereinafter as a COMBINATION OF THE INVENTION.
- anti-epileptic drugs selected from barbiturates and derivatives thereof, benzodiazepines, carboxamides, hydantoins, succinimides, valproic acid and other fatty acid derivates and other anti-epileptic drugs
- conventional antipsychotics and
- atypical antipsychotics
- a COMBINATION OF THE INVENTION results in a beneficial, especially a synergistic, therapeutic effect or in other surprising beneficial effects, e.g. less side effects, compared to a monotherapy applying only one of the pharmaceutically active ingredients used in the COMBINATION OF THE INVENTION.
- the antipsychotic potential of a COMBINATION OF THE INVENTION may, for example, be evidenced in preclinical studies known as such, e.g. the methods described herein.
- the antipsychotic potential of the COMBINATION OF THE INVENTION is indicated in standard tests, e.g. in the amphetamine-induced hyperlocomotion test. Blockade of amphetamine-induced hyperlocomotion is well known as screening paradigm for antischizophrenic activity.
- Threshold doses of each active ingredient of the combination partners are used.
- Amphetamine is dosed at 1 mg/kg s.c.
- Locomotion is recorded with a videotracking system. Animals are on a normal 12/12 h. day-night cycle, with light on at 06:00 H. Experiments are performed in a dimly lit room between 07:00 H and 15:00 H. Animals are placed in a round arena (diameter 42 cm, height 32 cm) made of grey polyvinylchloride plastic. The camera is placed such, that four animals (one per arena) can be recorded simultaneously.
- the pharmacological activity of a COMBINATION OF THE INVENTION may, for example, be demonstrated in a clinical study.
- Such clinical studies are preferably randomized, double-blind, clinical studies in patients with schizophrenia.
- Such studies demonstrate, in particular, the synergism of the active ingredients of the COMBINATIONS OF THE INVENTION.
- the beneficial effects on schizophrenia can be determined directly through the results of these studies or by changes in the study design which are known as such to a person skilled in the art.
- the studies are, in particular, suitable to compare the effects of a monotherapy using the active ingredients and a COMBINATION OF THE INVENTION.
- the COMBINATIONS OF THE INVENTION provide, in particular, benefits in the treatment of positive symptoms, negative symptoms, mood symptoms and/or cognitive symptoms of schizophrenia and/or psychosis. Furthermore, some of the COMBINATIONS OF THE INVENTION show beneficial effects in the control of impulsive and/or violent behavior of schizophrenic patients.
- a further benefit is that lower doses of the active ingredients of the COMBINATION OF THE INVENTION can be used, for example, that the dosages need not only often be smaller but are also applied less frequently, or can be used in order to diminish the incidence of side effects. This is in accordance with the desires and requirements of the patients to be treated.
- the COMBINATIONS OF THE INVENTION can be used, in particular, for the treatment of schizophrenia which is refractory to monotherapy.
- the AMPA receptor antagonists used in the present invention are competitive AMPA receptor antagonists.
- the COMBINATION OF THE INVENTION comprises an AMPA receptor antagonist, which is a quinoxalinedione aminoalkylphosphonate, in particular a quinoxalinedione aminoalkylphosphonate of formula I
- R-1 represents hydroxy or an aliphatic, aryl aliphatic or aromatic group
- X represents an aliphatic, cycloaliphatic, cycloaliphatic aliphatic, aryl aliphatic, heteroaryl aliphatic or aromatic group
- R 2 represents hydrogen or an aliphatic or aryl aliphatic group, alk stands for C1-C7alkylene, and
- R 3 , R 4 and R 5 represent independently of each other hydrogen, C1-C7alkyl, halogen, trifluoromethyl, cyano or nitro, and wherein the radicals have the meanings as defined in WO 98/17672.
- the COMBINATION OF THE INVENTION comprises an AMPA receptor antagonist which is a compound of formula I, wherein R- ⁇ represents hydroxyl, X represents methylene, R 2 represents hydrogen, alk stands for methylene, R 3 and R 5 represent hydrogen, and R 4 represents nitro or a salt thereof, i.e. is ⁇ [(7-Nitro-2,3-dioxo-1 ,2,3,4- tetrahydro-quinoxalin-5-ylmethyl)-amino]-methyl ⁇ -phosphonic acid or a salt thereof (cf. WO 97/08155, Example 57, 1st entry, and WO 98/17672, Example 12, 4th entry).
- the AMPA receptor antagonists is selected from EGIS 8332 (7-acetyl-5-(4-aminophenyl)-8,9-dihydro-8-methyl-7H-1 ,3- dioxolo[4,5-h][2,3]benzodiazepine-8-carbonitrile), GYKI 47261 4-(7-chloro-2-methyl- 4H-3,10,10a-triaza-benzo[f]azulen-9-yl)-phenylamine), irampanel (BUR 561; N,N- dimethyl-2-[2-(3-phenyl-1,2,4-oxadiazol-5-yl)phenoxy]ethanamine), KRP 199 (7-[4- [[[[(4-carboxyphenyl)-amino]carbonyl]oxy]methyl]-1H-imidazol-1-yl]-3,4-dihydro-3-oxo- 6-(trifluoromethyl)-2-quinox
- YM90K (6-imidazol-1-yl-7-nitro-1 ,4-dihydro-quinoxaline-2,3-dione), S-34730 (7-chloro-6-sulfamoyl-2-(1H)-quinolinone-3-phosphonic acid), Zonampanel (YM-872; (7-imidazol-1 -yl-6-nitro-2,3-dioxo-3,4-dihydro-2H-quinoxalin-1 -yl)-acetic acid), GYKI- 52466 (4-(8-methyl-9H-1 ,3-dioxa-6,7-diaza-cyclohepta[f]inden-5-yl)-phenylamine), ZK- 200775 (MPQX, (7-morpholin-4-yl-2,3-dioxo-6-trifluoromethyl-3,4-dihydro-2H- quinoxalin-1-ylmethyl)-phosphonic acid),
- It is one objective of this invention to provide a pharmaceutical composition comprising a quantity, which is jointly therapeutically effective against schizophrenia, comprises at least one AMPA antagonist, at least one compound selected from the group specified above and at least one pharmaceutically acceptable carrier.
- the first and second active ingredient can be administered together, one after the other or separately in one combined unit dosage form or in two separate unit dosage forms.
- the unit dosage form may also be a fixed combination.
- compositions according to the invention can be prepared in a manner known per se and are those suitable for enteral, such as oral or rectal, and parenteral administration to mammals (warm-blooded animals), including humans, comprising a therapeutically effective amount of at least one pharmacologically active ingredient, alone or in combination with one or more pharmaceutically acceptable carries, especially suitable for enteral or parenteral application.
- enteral such as oral or rectal
- parenteral administration to mammals (warm-blooded animals), including humans, comprising a therapeutically effective amount of at least one pharmacologically active ingredient, alone or in combination with one or more pharmaceutically acceptable carries, especially suitable for enteral or parenteral application.
- the preferred route of administration of the dosage forms of the present invention is orally.
- the novel pharmaceutical composition contain, for example, from about 10 % to about 100 %, preferably from about 20 % to about 60 %, of the active ingredients.
- Pharmaceutical preparations for the combination therapy for enteral or parenteral administration are, for example, those in unit dosage forms, such as sugar-coated tablets, tablets, capsules or suppositories, and furthermore ampoules. If not indicated otherwise, these are prepared in a manner known per se, for example by means of conventional mixing, granulating, sugar- coating, dissolving or lyophilizing processes. It will be appreciated that the unit content of active ingredient or ingredients contained in an individual dose of each dosage form need not in itself constitute an effective amount since the necessary effective amount can be reached by administration of a plurality of dosage units.
- any of the usual pharmaceutical media may be employed, such as, for example, water, glycols, oils or alcohols; or carriers such as starches, sugars, microcristalline cellulose, diluents, granulating agents, lubricants, binders, disintegrating agents and the like in the case of oral solid preparations such as, for example, powders, capsules and tablets. Because of their ease of administration, tablets and capsules represent the most advantageous oral dosage unit form in which case solid pharmaceutical carriers are obviously employed.
- the present invention relates to the use of a COMBINATION OF THE INVENTION for the preparation of a medicament for the treatment of schizophrenia.
- the present invention provides a method of treating a warm-blooded animal having schizophrenia comprising administering to the animal a COMBINATION OF THE INVENTION in a quantity which is jointly therapeutically effective against schizophrenia and in which the compounds can also be present in the form of their pharmaceutically acceptable salts.
- the present invention provides a commercial package comprising as active ingredients COMBINATION OF THE INVENTION, together with instructions for simultaneous, separate or sequential use thereof in the treatment of schizophrenia.
- a therapeutically effective amount of each of the active ingredients of the COMBINATION OF THE INVENTION may be administered simultaneously or sequentially and in any order, and the components may be administered separately or as a fixed combination.
- the method of treatment of schizophrenia according to the invention may comprise (i) administration of the first active ingredient in free or pharmaceutically acceptable salt form and (ii) administration of the second active ingredient in free or pharmaceutically acceptable salt form, simultaneously or sequentially in any order, in jointly therapeutically effective amounts, preferably in synergistically effective amounts, e.g. in daily dosages corresponding to the amounts described herein.
- the individual active ingredients of the COMBINATION OF THE INVENTION can be administered separately at different times during the course of therapy or concurrently in divided or single combination forms.
- administering also encompasses the use of a pro-drug of an active ingredient that convert in vivo to the active ingredient.
- the instant invention is therefore to be understood as embracing all such regimes of simultaneous or alternating treatment and the term "administering" is to be interpreted accordingly.
- the COMBINATION OF THE INVENTION is used for the treatment of treatment of schizophrenia which is refractory to monotherapy.
- the effective dosage of each of the active ingredients employed in the COMBINATION OF THE INVENTION may vary depending on the particular compound or pharmaceutical composition employed, the mode of administration, the severity of the condition being treated.
- the dosage regimen the COMBINATION OF THE INVENTION is selected in accordance with a variety of factors including the route of administration and the renal and hepatic function of the patient.
- a physician, clinician or veterinarian of ordinary skill can readily determine and prescribe the effective amount of the single active ingredients required to prevent, counter or arrest the progress of the condition.
- Optimal precision in achieving concentration of the active ingredients within the range that yields efficacy without toxicity requires a regimen based on the kinetics of the active ingredients' availability to target sites. This involves a consideration of the distribution, equilibrium, and elimination of the active ingredients.
- Phenobarbital may be administered to an adult patient in a total daily dosage between about 1 to about 3 mg/kg body weight and to a pediatric patient in a total daily dosage between about 3 to about 4 mg/kg body weight, split into two separate units.
- Primidone may be administered to an adult patient and to children being at least 9 years old in a total daily dosage of 0.75 to 1.5 g.
- Clonazepam may be administered to an adult patient in a total daily dosage between about 3 to about 8 mg and to a pediatric patient in a total daily dosage between about 0.5 to about 3 mg, split into three of four separate units.
- Diazepam may be administered to an adult patient in a total daily dosage between about 5 to about 10 mg and to a pediatric patient in a total daily dosage between about 5 to about 10 mg.
- Lorazepam may be administered to an adult patient in a total daily dosage between about . 0.044 mg/kg body weight to about 0.05 mg/kg body weight.
- Carbamazepine may be administered to an adult patient in a total daily dosage between about 600 to about 2000 mg and to a pediatric patient older than 6 years in a total daily dosage between about 400 to about 600 mg.
- Oxcarbazepine may be administered to an adult patient in a total daily dosage between about 600 to about 2400 mg and to a pediatric patient in a total daily dosage between about 30 to about 46 mg/kg body weight.
- Phenytoin may be administered to an adult patient in a total daily dosage between about 100 to about 300 mg and to a pediatric patient in a total daily dosage between about 100 to about 200 mg.
- Ethosuximide may be administered to an adult patient in a total daily dosage of about 15 mg/kg body weight and to a pediatric patient in a total daily dosage of about 20 mg/kg body weight.
- Valproic acid sodium salt may be administered to an adult patient in a total daily dosage of about 20 mg/kg body weight and to a pediatric patient in a total daily dosage of about 30 mg/kg body weight.
- Tiagabine hydrochloride monohydrate may be administered to an adult patient in a total daily dosage between about 15 to about 70 mg.
- Vigrabatrine may be administered to an adult patient in a total daily dosage between about 2 to about 3 g.
- Levetiracetam may be administered to patient who is older than 16 years in a total daily dosage between about 1000 to about 3000 mg.
- Lamotrigine may be administered to patient who is older than 12 years in a total daily dosage between about 100 to about 200 mg.
- Gabapentin may be administered to patient in a total daily dosage between about 900 to about 2400 mg.
- Sultiam may be administered to patient in a total daily dosage between about 5 to about 10 mg/kg body weight.
- Felbamate may be administered to patient who is older than 14 years in a total daily dosage of between about 2400 to about 3600 mg.
- Topiramate may be administered to an adult patient in a total daily dosage of between about 250 to about 500 mg.
- Clozaril may be administered to an adult patient in a total daily dosage of between about 300 to about 900 mg.
- Haloperidol may be administered to a patient in a total daily dosage of between about 2.5 to about 30 mg.
- Olanzapine can be administered to a patient in a total daily dosage of between about 2.5 to about 20 mg.
- Quetiapine can be administered to a patient in a total daily dosage of between about 500 to about 600 mg. Risperidone may be administered to a patient in a total daily dosage of between about 2 to about 6 mg.
- ⁇ [(7-Nitro-2,3-dioxo-1 ,2,3,4-tetrahydro-quinoxalin-5-ylmethyl)-amino]-methyl ⁇ -phosphonic acid may be administered to a patient in a total daily dosage of about 60 to about 400 mg.
- Talampanel may be administered to a patient in a total daily dosaqe of between 25 to about 75 mg
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP04790923A EP1682157A1 (en) | 2003-10-28 | 2004-10-27 | Combinations comprising ampa receptor antagonists for the treatment of schizophrenia |
JP2006537176A JP2007509883A (en) | 2003-10-28 | 2004-10-27 | Combinations comprising AMPA receptor antagonists for the treatment of schizophrenia |
CA002541293A CA2541293A1 (en) | 2003-10-28 | 2004-10-27 | Combinations comprising ampa receptor antagonists for the treatment of schizophrenia |
MXPA06004780A MXPA06004780A (en) | 2003-10-28 | 2004-10-27 | Combinations comprising ampa receptor antagonists for the treatment of schizophrenia. |
AU2004290890A AU2004290890B2 (en) | 2003-10-28 | 2004-10-27 | Combinations comprising AMPA receptor antagonists for the treatment of schizophrenia |
BRPI0415966-7A BRPI0415966A (en) | 2003-10-28 | 2004-10-27 | combinations comprising ampa receptor antagonists for treatment of schizophrenia |
US10/577,196 US20070082873A1 (en) | 2003-10-28 | 2004-10-27 | Combinations comprising ampa receptor antagonists for the treatment of schizophrenia |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB0325175.8 | 2003-10-28 | ||
GBGB0325175.8A GB0325175D0 (en) | 2003-10-28 | 2003-10-28 | Organic compounds |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2005049040A1 true WO2005049040A1 (en) | 2005-06-02 |
Family
ID=29725529
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2004/012150 WO2005049040A1 (en) | 2003-10-28 | 2004-10-27 | Combinations comprising ampa receptor antagonists for the treatment of schizophrenia |
Country Status (10)
Country | Link |
---|---|
US (1) | US20070082873A1 (en) |
EP (1) | EP1682157A1 (en) |
JP (1) | JP2007509883A (en) |
CN (1) | CN1874779A (en) |
AU (1) | AU2004290890B2 (en) |
BR (1) | BRPI0415966A (en) |
CA (1) | CA2541293A1 (en) |
GB (1) | GB0325175D0 (en) |
MX (1) | MXPA06004780A (en) |
WO (1) | WO2005049040A1 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9346790B2 (en) | 2010-12-06 | 2016-05-24 | Autifony Therapeutics Limited | Hydantoin derivatives useful as Kv3 inhibitors |
US9422252B2 (en) | 2012-05-22 | 2016-08-23 | Autifony Therapeutics Limited | Triazoles as Kv3 inhibitors |
US9669030B2 (en) | 2012-05-22 | 2017-06-06 | Autifony Therapeutics Limited | Hydantoin derivatives as Kv3 inhibitors |
US9849131B2 (en) | 2009-12-11 | 2017-12-26 | Autifony Therapeutics Limited | Imidazolidinedione derivatives |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2010505811A (en) * | 2006-10-04 | 2010-02-25 | ファイザー・プロダクツ・インク | Pyrido [4,3-d] pyrimidin-4 (3H) -one derivatives as calcium receptor antagonists |
US11977085B1 (en) | 2023-09-05 | 2024-05-07 | Elan Ehrlich | Date rape drug detection device and method of using same |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998017672A1 (en) * | 1996-10-24 | 1998-04-30 | Novartis Ag | Substituted aminoalkane phosphonic acids |
WO2003092701A2 (en) * | 2002-04-30 | 2003-11-13 | Novartis Ag | Substituted aminoalkanephosphonic acids for the treatment of neuropathic pain, affective and attention disorders, schizophrenia, tinnitus, myopia and other ocular disorders |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP0424179A3 (en) * | 1989-10-20 | 1991-12-27 | John William Olney | Use of combined excitatory amino acid and cholinergic antagonists to prevent neurological deterioration |
GB9022785D0 (en) * | 1990-10-19 | 1990-12-05 | Merck Sharp & Dohme | Therapeutic agents |
US5891871A (en) * | 1996-03-21 | 1999-04-06 | Cocensys, Inc. | Substituted 2,3-benzodiazepin-4-ones and the use thereof |
AU745641B2 (en) * | 1997-10-27 | 2002-03-28 | Cortex Pharmaceuticals, Inc. | Treatment of schizophrenia with ampakines and neuroleptics |
US6420369B1 (en) * | 1999-05-24 | 2002-07-16 | Ortho-Mcneil Pharmaceutical, Inc. | Anticonvulsant derivatives useful in treating dementia |
US6486198B1 (en) * | 1999-05-28 | 2002-11-26 | Jeffrey Berlant | Compounds and methods for the treatment of post traumatic stress disorder |
US6191117B1 (en) * | 2000-07-10 | 2001-02-20 | Walter E. Kozachuk | Methods of producing weight loss and treatment of obesity |
WO2003066039A1 (en) * | 2002-02-08 | 2003-08-14 | Abbott Laboratories | Combination therapy for treatment of schizophrenia |
DE10332473A1 (en) * | 2003-07-16 | 2005-02-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ambroxol for the treatment of epilepsy |
DE10332487A1 (en) * | 2003-07-16 | 2005-02-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ambroxol for the treatment of chronic nociceptive pain |
-
2003
- 2003-10-28 GB GBGB0325175.8A patent/GB0325175D0/en not_active Ceased
-
2004
- 2004-10-27 MX MXPA06004780A patent/MXPA06004780A/en not_active Application Discontinuation
- 2004-10-27 EP EP04790923A patent/EP1682157A1/en not_active Withdrawn
- 2004-10-27 AU AU2004290890A patent/AU2004290890B2/en not_active Ceased
- 2004-10-27 CN CNA2004800316615A patent/CN1874779A/en active Pending
- 2004-10-27 JP JP2006537176A patent/JP2007509883A/en active Pending
- 2004-10-27 WO PCT/EP2004/012150 patent/WO2005049040A1/en active Application Filing
- 2004-10-27 CA CA002541293A patent/CA2541293A1/en not_active Abandoned
- 2004-10-27 BR BRPI0415966-7A patent/BRPI0415966A/en not_active IP Right Cessation
- 2004-10-27 US US10/577,196 patent/US20070082873A1/en not_active Abandoned
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998017672A1 (en) * | 1996-10-24 | 1998-04-30 | Novartis Ag | Substituted aminoalkane phosphonic acids |
WO2003092701A2 (en) * | 2002-04-30 | 2003-11-13 | Novartis Ag | Substituted aminoalkanephosphonic acids for the treatment of neuropathic pain, affective and attention disorders, schizophrenia, tinnitus, myopia and other ocular disorders |
Non-Patent Citations (9)
Title |
---|
CHIMIRRI A ET AL: "AMPA receptor antagonists", EXPERT OPINION ON THERAPEUTIC PATENTS 1999 UNITED KINGDOM, vol. 9, no. 5, 1999, pages 557 - 570, XP002316062, ISSN: 1354-3776 * |
DEUTSCH STEPHEN I ET AL: "A revised excitotoxic hypothesis of schizophrenia: Therapeutic implications", CLINICAL NEUROPHARMACOLOGY, vol. 24, no. 1, January 2001 (2001-01-01), pages 43 - 49, XP009043407, ISSN: 0362-5664 * |
DRAPALSKI AMY L ET AL: "Topiramate improves deficit symptoms in a patient with schizophrenia when added to a stable regimen of antipsychotic medication", CLINICAL NEUROPHARMACOLOGY, vol. 24, no. 5, September 2001 (2001-09-01), pages 290 - 294, XP009043406, ISSN: 0362-5664 * |
GLICK I D ET AL: "PSYCHOPHARMACOLOGIC TREATMENT STRATEGIES FOR DEPRESSION, BIPOLAR DISORDER, AND SCHIZOPHRENIA", ANNALS OF INTERNAL MEDICINE, NEW YORK, NY, US, vol. 134, no. 1, 2 January 2001 (2001-01-02), pages 47 - 60, XP009000276, ISSN: 0003-4819 * |
HOSAK L ET AL: "Antiepileptic drugs in schizophrenia: A review.", EUROPEAN PSYCHIATRY, vol. 17, no. 7, November 2002 (2002-11-01), pages 371 - 378, XP002316065, ISSN: 0924-9338 * |
KALKMAN H O: "ANTISCHIZOPHRENIC ACTIVITY INDEPENDENT OF DOPAMINE D2 BLOCKADE", EXPERT OPINION ON THERAPEUTIC TARGETS, ASHLEY PUBLICATIONS, LONDON, GB, vol. 6, no. 5, 2002, pages 571 - 582, XP008020037, ISSN: 1472-8222 * |
LEES GORDON J: "Pharmacology of AMPA/kainate receptor ligands and their therapeutic potential in neurological and psychiatric disorders", DRUGS, vol. 59, no. 1, January 2000 (2000-01-01), pages 33 - 78, XP009043409, ISSN: 0012-6667 * |
MÖLLER HANS-JÜRGEN: "Management of the negative symptoms of schizophrenia: new treatment options.", CNS DRUGS. 2003, vol. 17, no. 11, 2003, pages 793 - 823, XP009043416, ISSN: 1172-7047 * |
See also references of EP1682157A1 * |
Cited By (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9849131B2 (en) | 2009-12-11 | 2017-12-26 | Autifony Therapeutics Limited | Imidazolidinedione derivatives |
US10058551B2 (en) | 2009-12-11 | 2018-08-28 | Autifony Therapeutics Limited | Imidazolidinedione derivatives |
US10632118B2 (en) | 2009-12-11 | 2020-04-28 | Autifony Therapeutics Limited | Imidazolidinedione derivatives |
US9346790B2 (en) | 2010-12-06 | 2016-05-24 | Autifony Therapeutics Limited | Hydantoin derivatives useful as Kv3 inhibitors |
US10265316B2 (en) | 2010-12-06 | 2019-04-23 | Autifony Therapeuctics Limited | Hydantoin derivatives useful as Kv3 inhibitors |
US11197859B2 (en) | 2010-12-06 | 2021-12-14 | Autifony Therapeutics Limited | Hydantoin derivatives useful as Kv3 inhibitors |
US11583527B2 (en) | 2010-12-06 | 2023-02-21 | Autifony Therapeutics Limited | Hydantoin derivatives useful as Kv3 inhibitors |
US9422252B2 (en) | 2012-05-22 | 2016-08-23 | Autifony Therapeutics Limited | Triazoles as Kv3 inhibitors |
US9669030B2 (en) | 2012-05-22 | 2017-06-06 | Autifony Therapeutics Limited | Hydantoin derivatives as Kv3 inhibitors |
US10160730B2 (en) | 2012-05-22 | 2018-12-25 | Autifony Therapeutics Limited | Triazoles as KV3 inhibitors |
US10611735B2 (en) | 2012-05-22 | 2020-04-07 | Autifony Therapeutics Limited | Triazoles as Kv3 inhibitors |
US11180461B2 (en) | 2012-05-22 | 2021-11-23 | Autifony Therapeutics Limited | Triazoles as Kv3 inhibitors |
Also Published As
Publication number | Publication date |
---|---|
JP2007509883A (en) | 2007-04-19 |
CN1874779A (en) | 2006-12-06 |
US20070082873A1 (en) | 2007-04-12 |
BRPI0415966A (en) | 2007-01-23 |
GB0325175D0 (en) | 2003-12-03 |
AU2004290890A1 (en) | 2005-06-02 |
CA2541293A1 (en) | 2005-06-02 |
EP1682157A1 (en) | 2006-07-26 |
MXPA06004780A (en) | 2006-07-03 |
AU2004290890B2 (en) | 2008-10-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP1871749B1 (en) | Selurampanel | |
JP2007517901A (en) | Antispasmodic and antipsychotic compositions that affect weight loss | |
KR20060011873A (en) | Therapeutic combinations of atypical antipsychotics with gaba modulators and/or anticonvulsant drugs | |
JP2007262096A (en) | Composition and method for treating or preventing convulsion or seizure | |
Sorbera et al. | Pagoclone | |
JP2009539996A (en) | Method for improving diuresis in individuals with renal dysfunction | |
CA2568436A1 (en) | Combination therapy comprising an adenosine a1 receptor antagonist and an aldosterone inhibitor | |
AU2004290890B2 (en) | Combinations comprising AMPA receptor antagonists for the treatment of schizophrenia | |
AU2004226825B2 (en) | Combinations comprising anti-epileptic drugs for the treatment of neurological disorders | |
NZ527991A (en) | Carbamate compounds for use in preventing or treating psychotic disorders | |
CA2479495A1 (en) | Remedy for glioblastoma | |
AU2003267557B2 (en) | Treatment of dyskinesia | |
WO2005094797A2 (en) | Use of ampa-receptor antagonists for treating dementia | |
WO2005049039A1 (en) | Combinations comprising ampa receptors antagonists for the treatment of affective and attention deficit disorders | |
WO2005049042A1 (en) | Combinations comprising ampa receptor antagonists for the treatment of tinnitus | |
WO2005049041A1 (en) | Combinations comprising ampa receptor antagonists for the treatment of anxiety disorders | |
EP1545546B1 (en) | Treatment of dyskinesia with 2,3-benzodiazepines | |
WO2005039593A1 (en) | Combinations comprising ampa receptor antagonists for the treatment of neuropathic pain | |
WO2005097138A2 (en) | Combinations comprising oxcarbazepine to treat affective disorders | |
WO2005039594A1 (en) | Combinations comprising ampa receptor antagonists for the treatment of myopia | |
EP1815854A1 (en) | Treatment of dyskenesia | |
CA2617420A1 (en) | Therapeutic combinations of atypical antipsychotics with gaba modulators, anticonvulsants or benzodiazapines | |
MXPA02005071A (en) | Compositions comprising s-tofisopam and use of these |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200480031661.5 Country of ref document: CN |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2004790923 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2004290890 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2541293 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref document number: 2004290890 Country of ref document: AU Date of ref document: 20041027 Kind code of ref document: A |
|
WWP | Wipo information: published in national office |
Ref document number: 2004290890 Country of ref document: AU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1427/CHENP/2006 Country of ref document: IN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006537176 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2006/004780 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2007082873 Country of ref document: US Ref document number: 10577196 Country of ref document: US |
|
WWP | Wipo information: published in national office |
Ref document number: 2004790923 Country of ref document: EP |
|
ENP | Entry into the national phase |
Ref document number: PI0415966 Country of ref document: BR |
|
WWP | Wipo information: published in national office |
Ref document number: 10577196 Country of ref document: US |